OrbiMed

Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, that specializes in developing small molecule therapies for severe, rare musculoskeletal diseases. Founded in 2017, the company employs a precision medicine approach to create innovative treatments targeting various muscle disorders, including Duchenne and Becker muscular dystrophies, as well as limb girdle muscular dystrophies. Utilizing its proprietary muscle-focused drug discovery platform, Edgewise integrates expertise in muscle biology and small molecule engineering to identify and develop therapies that address genetically defined muscle disorders. The company emphasizes a holistic drug discovery method that assesses integrated muscle function, enabling it to create orally bioavailable therapies aimed at improving outcomes for patients with significant unmet medical needs in neuromuscular and cardiac diseases.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly ABI-009, aimed at treating patients with alterations in the TSC1 or TSC2 genes, where existing mTOR inhibitors have limitations in pharmacology, drug delivery, or safety. Aadi's primary focus is on providing transformational therapies for patients with ultra-rare cancers, such as perivascular epithelioid cell tumors (PEComa). Since its founding in 2011, Aadi Bioscience has aimed to address significant unmet medical needs in oncology and related therapeutic areas.

Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Established in 2011, the company has developed therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of nasal congestion. Its primary products include the VivAer procedure for nasal airway obstruction and the RhinAer procedure for chronic rhinitis, both of which employ proprietary temperature-controlled technology. These solutions offer ENT physicians appealing alternatives to invasive surgery, allowing them to treat patients under local anesthesia with minimal to no downtime. Aerin Medical aims to meet the unmet needs of individuals suffering from chronic nasal airway conditions through its innovative and office-friendly product offerings.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly ABI-009, aimed at treating patients with alterations in the TSC1 or TSC2 genes, where existing mTOR inhibitors have limitations in pharmacology, drug delivery, or safety. Aadi's primary focus is on providing transformational therapies for patients with ultra-rare cancers, such as perivascular epithelioid cell tumors (PEComa). Since its founding in 2011, Aadi Bioscience has aimed to address significant unmet medical needs in oncology and related therapeutic areas.

SiteOne Therapeutics is a San Francisco-based company focused on developing innovative therapeutics and diagnostics for the treatment of acute and chronic pain. The company aims to address the limitations of existing pain management therapies, such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, by creating safer and more effective alternatives. Their lead candidates are highly selective inhibitors of the voltage-gated sodium ion channel Naᵥ1.7, which is crucial in the generation and conduction of pain signals. By targeting this channel, SiteOne Therapeutics seeks to provide healthcare professionals with advanced treatment options for neuropathic pain, ultimately improving patient outcomes and efficiency in pain management.

Leal Therapeutics is a Massachusetts-based company focused on developing innovative therapeutics for patients with significant central nervous system conditions. The company addresses urgent and unmet medical needs by providing precision medicines tailored to improve patient outcomes. Through its dedication to advancing therapeutic services, Leal Therapeutics aims to enhance the quality of care for individuals affected by challenging neurological disorders.

MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Established in 2018, the company focuses on creating peptides aimed at treating genetic diseases that affect glandular hormones, which play a crucial role in the body’s chemical messaging system. By targeting conditions with inadequate treatment options, MBX Biosciences is dedicated to discovering, developing, and commercializing innovative endocrine therapeutics.

Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company based in Burlingame, California, dedicated to developing innovative immuno-oncology therapies. The company’s lead product candidate, Ciforadenant (CPI-444), is an oral small molecule antagonist of the A2A receptor and is currently undergoing Phase Ib/2 clinical trials. Additionally, Corvus is advancing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib trials aimed at inhibiting adenosine production and stimulating immune responses, as well as investigating its potential for treating COVID-19. Another candidate, CPI-818, is a small molecule that selectively inhibits interleukin-2-inducible T-cell kinase and is also in Phase I/Ib trials. Corvus Pharmaceuticals collaborates strategically with Angel Pharmaceuticals to enhance its pipeline of targeted investigational medicines. Founded in 2014, the company is focused on addressing significant unmet medical needs in cancer treatment and related diseases.

TriSalus Life Sciences, based in Westminster, Colorado, focuses on developing innovative drug delivery technologies and immune-oncology therapeutics aimed at improving treatment outcomes for challenging cancers, particularly liver and pancreatic cancer. Founded in 2009, the company specializes in precision infusion systems designed for interventional radiology. Its product offerings include Pressure Enabled Drug Delivery (PEDD) systems, which utilize a unique expandable tip catheter to deliver embolic agents while minimizing damage to healthy tissues. The Surefire infusion systems, including various models for lobar, segmental, and super-selective infusions, aim to enhance tumor uptake through controlled pressure and blood flow management. Additionally, TriSalus is advancing an investigational therapy, nelitolimod, which has shown promise in enhancing immune response against liver tumors. The company continues to innovate with devices like the TriNav, which employs SmartValve technology to optimize drug delivery.

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for disorders related to corticosteroid excess. Founded in 2013 by David A. Katz and based in Portland, Oregon, the company aims to provide better therapeutic options for patients suffering from hypercortisolism and autoimmune or inflammatory conditions. By utilizing unique insights into corticosteroid biology, Sparrow is advancing its lead product, SPI-62, an oral small molecule treatment that specifically targets the source of active intracellular corticosteroids in critical tissues. This approach is designed to alleviate the adverse effects of both naturally occurring corticosteroids, such as cortisol due to tumors, and the long-term use of corticosteroid medications like prednisone.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.

Geron Corporation is a late-stage clinical biopharmaceutical company headquartered in Menlo Park, California, that specializes in developing therapies for hematologic myeloid malignancies. The company's lead product, imetelstat, is a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. This investigational drug aims to inhibit the uncontrolled proliferation of malignant progenitor cells, which can lead to dysfunctional blood cell production, thereby facilitating the recovery of normal blood cell development. Founded in 1990, Geron focuses on advancing treatments for conditions such as myelodysplastic syndromes and myelofibrosis, a rare blood cancer affecting bone marrow. The company also generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Pinnacle Medicines is a peptide drug discovery company located in Doylestown, Pennsylvania. The company specializes in developing peptide-based therapeutics to address unmet medical needs. Utilizing AI-driven drug design tools, Pinnacle Medicines focuses on creating safe and effective treatments for medical applications. Through its innovative approach, the company aims to enhance the availability of convenient and reliable therapeutics for various health challenges.

BioAge Labs, Inc. is a biotechnology company focused on developing therapies to address aging and age-related diseases. The company utilizes a systems biology and artificial intelligence platform to identify key drug targets that influence aging and analyze extensive datasets to uncover the molecular drivers of age-related conditions. BioAge Labs is advancing several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to activate genes involved in critical biological processes such as tissue regeneration and vascular remodeling. Additionally, BGE-175, an orally administered inhibitor of the prostaglandin D2 DP1 signaling pathway, aims to mitigate risks associated with immune aging and respiratory infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to discovering and developing innovative treatments that harness the biology of human aging.

Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California, that specializes in developing small molecule therapies for cancer treatment. Founded in 2018, the company aims to address drug resistance in cancer therapies through its proprietary SNÅP platform, which facilitates rapid and precise drug design by generating iterative molecular snapshots. Tyra is particularly focused on creating selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family, which are implicated in approximately 7% of all cancers. The company's lead product candidate, TYRA-300, specifically targets FGFR3 and is initially aimed at patients with metastatic urothelial carcinoma of the bladder and urinary tract. Through its innovative approach, Tyra Biosciences seeks to improve treatment outcomes for cancer patients by providing alternatives to existing therapies.

Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on restless leg syndrome. Its innovative device utilizes neural circuitry to alleviate symptoms and promote undisturbed sleep, empowering patients to better manage their chronic medical conditions.

Koya Medical, Inc., founded in 2018 and based in Oakland, California, specializes in developing innovative therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. The company focuses on creating wearable technology that delivers active compression therapy, which is designed to enhance movement and mobility for patients. Koya Medical's approach offers a personalized alternative to traditional compression methods, utilizing a sensor-based closed-loop system to provide tailored compression patterns. This technology addresses the needs of patients suffering from conditions such as lymphedema, chronic edema, and chronic venous insufficiency, thereby improving their quality of care and overall treatment outcomes.

Avita Medical Inc. is a commercial-stage regenerative tissue company headquartered in Valencia, California, specializing in innovative treatment solutions for burn injuries, chronic wounds, and dermatological conditions. The company leverages its proprietary technology to harness the regenerative properties of a patient’s own skin, with its lead product being the RECELL System. This device allows healthcare professionals to create a suspension of Spray-On Skin cells from a small sample of the patient's skin, facilitating the treatment of acute thermal burns in adults. Avita is currently focusing its efforts on the U.S. market, where the RECELL System is being rolled out across approximately 136 burn centers, while also exploring clinical trials for expanded indications, including pediatric applications and soft-tissue reconstruction. The company has established research collaborations with various institutions to advance its development initiatives, including potential treatments for conditions like epidermolysis bullosa and skin rejuvenation.

Evozyne, LLC is a biotechnology company based in Chicago, Illinois, focused on protein design and molecular engineering. Founded in 2020, it utilizes a generative AI platform to create novel proteins with advanced functionality, addressing complex human and societal challenges. The company operates multiple business units, including Evozyne Industrial, Evozyne Agriculture, Evozyne Energy, Evozyne Biopharmaceuticals, and Evozyne Environmental. Its technology provides consistent models for protein behavior, enabling the development of customized proteins that can address various health-related issues and improve industrial processes. By revolutionizing protein design, Evozyne aims to unlock the potential of proteins in therapeutic discovery and drug development.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

Vicore Pharma Holding is a clinical-stage pharmaceutical company that specializes in developing innovative treatments for severe lung disorders, particularly idiopathic pulmonary fibrosis (IPF). The company is advancing its lead drug candidate, C21, a small molecule angiotensin II type 2 receptor agonist, which is currently in phase 2a clinical development for IPF and has received orphan drug designation in both the EU and the US. In addition to C21, Vicore is exploring pre-clinical applications of the drug in other rare diseases associated with the AT2 receptor. The company is also developing Almee, a digital therapeutic that utilizes cognitive behavioral therapy to address the psychological challenges faced by patients with pulmonary fibrosis. Headquartered in Astra Zeneca’s Bioventurehub in Mölndal, Vicore Pharma aims to establish a comprehensive portfolio targeting respiratory diseases.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

Caris Life Sciences, Inc. is a biotechnology company specializing in molecular profiling and advanced diagnostic technologies aimed at improving cancer patient outcomes. Founded in 1987 and headquartered in Irving, Texas, with additional offices in Phoenix and Basel, the company develops solutions that leverage artificial intelligence and machine learning to analyze the molecular complexity of diseases. Caris offers a range of services, including anatomic pathology, drug development, and molecular analyses of patient samples, which include genomic, transcriptomic, and proteomic profiling. Their Comprehensive Oncology Data Explorer serves as a clinico-genomic data platform. By providing insights into DNA, RNA, and protein profiles, Caris enables healthcare professionals to make more precise and personalized treatment decisions for oncology and other complex diseases. The company operates through distributors across the United States, Europe, Australia, and globally, and has established strategic collaborations to enhance its offerings.

Apogee Therapeutics is a biotechnology company based in San Francisco, California, founded in 2022. The company focuses on developing differentiated biologics for the treatment of immunological and inflammatory disorders, specifically targeting atopic dermatitis and chronic obstructive pulmonary disease. Apogee Therapeutics aims to address high unmet medical needs by advancing novel therapies that utilize advanced antibody engineering to enhance therapeutic properties such as half-life. The company's key programs, APG777 and APG808, are designed to leverage established mechanisms of action to improve treatment outcomes for patients suffering from these conditions.

MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Established in 2018, the company focuses on creating peptides aimed at treating genetic diseases that affect glandular hormones, which play a crucial role in the body’s chemical messaging system. By targeting conditions with inadequate treatment options, MBX Biosciences is dedicated to discovering, developing, and commercializing innovative endocrine therapeutics.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

PIC Therapeutics, Inc. is a biotechnology company dedicated to innovating cancer treatment through the selective modulation of oncogene translation. Founded in 2016 and based in Boston, Massachusetts, the company focuses on developing therapeutics that target the "master switch" of cancer signaling pathways. By modulating the pre-initiation complex responsible for messenger RNA translation, PIC Therapeutics aims to selectively block the production of oncogene proteins. This precision-based approach has the potential to simultaneously address multiple oncogenic drivers, thereby improving patient outcomes and advancing a new generation of cancer treatments.

Insmed Incorporated is a global biopharmaceutical company dedicated to improving the lives of patients with serious and rare diseases. Its flagship product, ARIKAYCE (amikacin liposome inhalation suspension), is approved in the United States for treating Mycobacterium avium complex (MAC) lung disease, targeting adult patients who have limited or no alternative treatment options. MAC lung disease is a rare and potentially fatal infection that can lead to significant lung damage. In addition to ARIKAYCE, Insmed's clinical pipeline features Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which shows promise for treating non-cystic fibrosis bronchiectasis and other inflammatory conditions. Another candidate in development is INS1009, an inhaled formulation of a treprostinil prodrug aimed at addressing rare pulmonary disorders, including pulmonary arterial hypertension.

Treeline Biosciences is a biotechnology company established in 2021 and based in Stamford, Connecticut. The company focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. Utilizing a comprehensive drug discovery platform, Treeline combines mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science to create innovative therapeutic solutions. Through its research and development efforts, Treeline aims to provide effective treatments to improve patient outcomes in oncology and beyond.

Adaptive Biotechnologies Corporation is a commercial-stage company focused on advancing immune-driven medicine by leveraging the biology of the adaptive immune system to enhance disease diagnosis and treatment. Established in 2009 and headquartered in Seattle, Washington, the company offers a range of products and services, including its FDA-authorized clonoSEQ diagnostic test, which is designed for the detection and monitoring of minimal residual disease in patients with specific blood cancers, such as multiple myeloma and chronic lymphocytic leukemia. In addition to clonoSEQ, Adaptive Biotechnologies provides immunoSEQ research services and kits to support scientific research and the discovery of new diagnostic signals. The company also has a pipeline of clinical products aimed at diagnosing and managing various diseases, including cancers, autoimmune disorders, and infectious diseases. It maintains strategic collaborations with notable partners such as Genentech and Microsoft to develop innovative therapies and diagnostic tests.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Established in 2011, the company has developed therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of nasal congestion. Its primary products include the VivAer procedure for nasal airway obstruction and the RhinAer procedure for chronic rhinitis, both of which employ proprietary temperature-controlled technology. These solutions offer ENT physicians appealing alternatives to invasive surgery, allowing them to treat patients under local anesthesia with minimal to no downtime. Aerin Medical aims to meet the unmet needs of individuals suffering from chronic nasal airway conditions through its innovative and office-friendly product offerings.

Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

MDClone Ltd. is a company that specializes in developing software for analyzing medical records while ensuring the privacy of patient data. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients, which allows researchers to study disease behavior, healthcare practices, and treatment outcomes without exposing actual patient information. The MDClone ADAMS Platform provides a self-service data analytics environment that facilitates exploration, discovery, and collaboration across healthcare systems, both nationally and internationally. This innovative approach addresses common barriers in healthcare by enabling users to organize and access data efficiently, thereby improving operations and enhancing patient outcomes. MDClone serves various clients in the healthcare sector, including major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Leal Therapeutics is a Massachusetts-based company focused on developing innovative therapeutics for patients with significant central nervous system conditions. The company addresses urgent and unmet medical needs by providing precision medicines tailored to improve patient outcomes. Through its dedication to advancing therapeutic services, Leal Therapeutics aims to enhance the quality of care for individuals affected by challenging neurological disorders.

Cyrus Biotechnology, Inc. is a Seattle-based company that specializes in developing advanced software for protein structure prediction and design. Founded in 2014, it offers several key products, including Rosetta, a tool designed to create biologically active proteins for various medical applications such as treating brain cancer and addressing Celiac Disease. The company also provides Cyrus Bench, an enterprise version of Rosetta that includes a comprehensive suite of bio-molecular computation tools. Additionally, Cyrus Biotechnology offers specialized services like Cyrus CryoEM, which focuses on structure refinement and model building for complex biomolecular structures. Its innovative software solutions cater to pharmaceutical companies, biotech firms, and startups engaged in discovering therapeutics and developing novel consumer products.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, dedicated to the development and commercialization of its lead drug candidate, TRC101. This non-absorbed, orally-administered polymer is designed to treat metabolic acidosis, a condition often associated with chronic kidney disease (CKD). Metabolic acidosis can contribute to the progression of CKD and is linked to various health issues such as muscle wasting, loss of bone density, and increased mortality risk. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, aiming to provide an effective treatment option for patients suffering from this condition. The company was founded in 2013 and is focused on addressing the unmet medical needs of individuals with CKD.

PierianDx, Inc. is a biotechnology company that specializes in developing a cloud-based genomic software solution aimed at managing, analyzing, and interpreting complex genomic tests for clinical laboratories in the United States. Founded in 2014 and headquartered in Saint Louis, Missouri, PierianDx offers its Clinical Genomicist Workstation, which streamlines the workflow for patient cases, encompassing aspects from case accessioning to final report generation and integration with electronic health records. The company's software employs artificial intelligence to enhance the efficiency of genomic sequencing processes, thereby empowering healthcare providers to better diagnose and treat patients with cancer and other complex diseases. PierianDx also provides consulting and technical services, and collaborates strategically with organizations like RTI International. Through its accredited laboratory and extensive knowledgebase, the company supports health systems, children's hospitals, comprehensive cancer centers, and commercial laboratories in delivering integrated genomic care.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Scout Bio, Inc. is a biotechnology company focused on developing innovative therapies for chronic health conditions in pets, utilizing veterinary biotechnology and gene therapy. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating one-time treatments to address significant issues such as anemia linked to chronic kidney disease in cats. Scout Bio employs Adeno-associated viral vector technology to design and deliver protein and monoclonal antibody therapeutics through single intra-muscular injections. The company's mission is to apply advancements from human medicine to improve veterinary care and enhance the quality of life for pets.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company leverages a proprietary scientific platform to transform native immune system proteins into innovative therapeutic candidates. Its leading programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator and CD28 pathways, designed for autoimmune and inflammatory conditions, and ALPN-303, a dual antagonist of the B cell activating factor and proliferation-inducing ligand, which is vital for B cell activation and survival. Additionally, Alpine Immune Sciences has established a collaboration with Kite Pharma to explore immunotherapies targeting the immune synapse for cancer treatment.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Humacyte, Inc. is a medical research and development company based in Morrisville, North Carolina, focused on creating and commercializing human tissue-based products for regenerative medicine and vascular surgery. The company specializes in designing acellular extracellular matrices, which are crafted in vitro from banked vascular smooth muscle cells and decellularized to prevent rejection. These products serve as tissue-engineered grafts for patients requiring vascular repair or replacement. Humacyte's innovative approach aims to provide universally implantable bioengineered human tissues and organs, addressing various diseases, injuries, and chronic conditions while enhancing patient care and transforming medical practices. Founded in 2004, the company is committed to advancing solutions for vascular diseases and the replacement of anatomical conduits.

Carrot Fertility, Inc. specializes in providing comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey on a global scale. The company's offerings include services such as egg freezing, in vitro fertilization, adoption, donor and gestational carrier services, as well as a premium pharmacy experience for fertility medications through Carrot Rx. Additionally, Carrot Pregnancy provides virtual access to experts and on-demand doctor-approved content, while the Carrot Card allows employees to use a flexible debit card for their fertility-related expenses. By customizing these benefits, Carrot Fertility aims to deliver financial, medical, and emotional support for individuals pursuing parenthood. Founded in 2015 and headquartered in San Francisco, California, the company also maintains offices in Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

XtalPi Inc. is a pharmaceutical technology company that focuses on digital drug development solutions, leveraging quantum mechanics and artificial intelligence to enhance the efficiency of drug research and development. Founded in 2014 by a group of quantum physicists at MIT, the company has developed its Intelligent Digital Drug Discovery and Development (ID4) platform, which integrates advanced cloud computing algorithms to aid pharmaceutical firms in critical stages of drug R&D. XtalPi offers various tools, including XtalForc for visual force field calculations, XtalVision for crystal structure predictions, and Renova for platform support of its AI research initiatives. Its comprehensive services encompass crystal structure determination, solid-state testing, small molecule drug design, and collaborations in antibody and peptide research. Based in Cambridge, Massachusetts, with additional offices in China, XtalPi has established strategic partnerships with leading international pharmaceutical companies, demonstrating the broad applicability and recognition of its innovative technologies across the pharmaceutical value chain.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs technologies. This innovative approach is designed to restore immune tolerance and address limitations present in current regulatory T-cell therapies. By targeting the underlying causes of diseases related to immune system dysfunction, GentiBio aims to provide effective therapeutic solutions for conditions that arise from immune system overshooting or malfunctioning. The company was co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of this emerging field.

Owlet Baby Care Inc. specializes in developing and manufacturing innovative monitoring solutions for infants, focusing on providing parents with real-time insights into their child's health. Founded in 2012 and based in Lehi, Utah, the company offers a range of products, including the Owlet Smart Sock, which tracks an infant's heart rate and oxygen levels while sleeping, alerting parents to any concerns. Additionally, the Owlet Cam allows parents to monitor their baby through their smartphones with high-definition clarity. The Owlet Monitor Duo combines the functionalities of the Smart Sock and the Cam for comprehensive monitoring. The company also provides the Owlet Dream Lab, an interactive program aimed at helping parents establish healthy sleep habits for their infants. Owlet's products are available for purchase online, ensuring accessibility for parents seeking peace of mind regarding their child's well-being.

Turnstone Biologics Inc. is a clinical-stage biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, the company is dedicated to advancing innovative viral immunotherapies aimed at improving cancer patient survival. Its lead product, RIVAL-01, utilizes a vaccinia virus backbone that encodes several immunomodulators, including Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, which work together to enhance immune activity and optimize the tumor microenvironment for effective cancer treatment. Additionally, Turnstone Biologics is developing next-generation tumor-infiltrating lymphocyte (TIL) therapies by isolating and expanding the most potent and tumor-reactive T cells from patients' tumors, thereby harnessing the body's own immune system to combat solid tumors. Through these innovative approaches, Turnstone Biologics aims to deliver breakthrough cancer immunotherapies that significantly improve clinical outcomes for patients.

Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

Biocytogen LLC is a biotechnology company based in Worcester, Massachusetts, that specializes in developing gene-targeted animal models for life science research. Founded in 2008, the company offers a range of services, including customized and off-the-shelf mouse models, phenotype analysis, and advanced gene-editing techniques. Its products encompass various types of mice, such as knockin and knockout models, as well as humanized mice, catering to diverse research areas including immunology, neurology, cancer, and infectious diseases. Biocytogen also operates a state-of-the-art animal facility to support its integrated platform for efficient antibody drug discovery and validation. The company collaborates with leading pharmaceutical and biotechnology firms to enhance preclinical research and development processes in the biomedical field.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for disorders related to corticosteroid excess. Founded in 2013 by David A. Katz and based in Portland, Oregon, the company aims to provide better therapeutic options for patients suffering from hypercortisolism and autoimmune or inflammatory conditions. By utilizing unique insights into corticosteroid biology, Sparrow is advancing its lead product, SPI-62, an oral small molecule treatment that specifically targets the source of active intracellular corticosteroids in critical tissues. This approach is designed to alleviate the adverse effects of both naturally occurring corticosteroids, such as cortisol due to tumors, and the long-term use of corticosteroid medications like prednisone.

Magenta Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies to enhance stem cell transplantation for patients with blood cancers, genetic diseases, and autoimmune disorders. The company aims to improve the safety and efficacy of stem cell transplants, which are currently high-risk procedures often considered only as a last resort. Its pipeline includes several key product candidates, such as targeted antibody-drug conjugates for transplant conditioning, a novel stem cell mobilization agent, and allogeneic stem cell therapies. Magenta is also exploring collaborations to assess the effectiveness of its therapies in combination with existing treatments, such as gene therapies for sickle cell disease. Founded in 2015 and headquartered in Cambridge, Massachusetts, Magenta Therapeutics seeks to expand the curative potential of stem cell therapies to a broader patient population by addressing the toxicity and long-term side effects associated with current transplant methods.

Caris Life Sciences, Inc. is a biotechnology company specializing in molecular profiling and advanced diagnostic technologies aimed at improving cancer patient outcomes. Founded in 1987 and headquartered in Irving, Texas, with additional offices in Phoenix and Basel, the company develops solutions that leverage artificial intelligence and machine learning to analyze the molecular complexity of diseases. Caris offers a range of services, including anatomic pathology, drug development, and molecular analyses of patient samples, which include genomic, transcriptomic, and proteomic profiling. Their Comprehensive Oncology Data Explorer serves as a clinico-genomic data platform. By providing insights into DNA, RNA, and protein profiles, Caris enables healthcare professionals to make more precise and personalized treatment decisions for oncology and other complex diseases. The company operates through distributors across the United States, Europe, Australia, and globally, and has established strategic collaborations to enhance its offerings.

Treeline Biosciences is a biotechnology company established in 2021 and based in Stamford, Connecticut. The company focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. Utilizing a comprehensive drug discovery platform, Treeline combines mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science to create innovative therapeutic solutions. Through its research and development efforts, Treeline aims to provide effective treatments to improve patient outcomes in oncology and beyond.

Scribe Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics based on CRISPR technology to address genetic disorders. Founded in 2017 and headquartered in Berkeley, California, the company utilizes its proprietary X-Editing (XE) platform, which features highly engineered CRISPR enzymes designed to improve the efficacy, specificity, and deliverability of genome editing. Scribe Therapeutics aims to overcome existing limitations in genetic medicine by creating custom-engineered enzymes and advanced delivery systems. Their approach seeks to establish CRISPR-based therapies as a new standard in clinical care, potentially transforming the treatment landscape for various conditions, including immuno-oncology, degenerative disorders, and enzyme replacement therapy. By prioritizing therapeutic precision and allele-specific targeting, Scribe Therapeutics is committed to expanding access to groundbreaking treatments that can significantly impact patient lives.

Crossover Health, established in 2010, specializes in providing comprehensive workplace healthcare services for employers and their employees. Headquartered in Aliso Viejo, California, with health centers across the United States, the company offers a wide range of services including primary care, urgent care, chronic disease management, health coaching, physical therapy, and more. Crossover Health aims to deliver exceptional member experiences and advanced health management services, ultimately promoting a healthy and motivated workforce for its clients.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Graphite Bio, Inc. is a clinical-stage gene editing company based in South San Francisco, California, that specializes in targeted DNA integration to develop innovative therapies for severe diseases. The company utilizes a precision gene editing approach to precisely correct genetic mutations, replace malfunctioning genes, and insert therapeutic genetic sequences at specific locations within the genome. Its technology aims to transform treatment paradigms by enabling the targeted integration of genetic payloads, which could potentially cure a range of serious and life-threatening conditions. Graphite Bio was formerly known as Integral Medicines, Inc. before rebranding in August 2020, and it was incorporated in 2019.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing new therapies for patients experiencing dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, creating therapeutic candidates that address molecular abnormalities in patients with significant clinical needs. Their diverse pipeline encompasses monoclonal antibodies, recombinant proteins, and gene therapies, positioning the company to potentially introduce first-in-class therapeutics. The development of these innovative treatment options is supported by collaborations with leading life science investors and academic institutions worldwide, reflecting a commitment to advancing medical care for individuals suffering from these conditions.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2019, the company utilizes artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By employing machine learning techniques, Delfi Diagnostics develops high-precision, non-invasive tests that aim to detect cancer at a stage when it is most treatable. Their technology enables healthcare professionals to recognize previously unrecognized cancer-associated cell-free DNA fragments, facilitating timely and effective treatment options for patients.

Noctrix Health, Inc. is an early-stage medical device company based in Menlo Park, California, founded in 2018. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on restless leg syndrome. Its innovative device utilizes neural circuitry to alleviate symptoms and promote undisturbed sleep, empowering patients to better manage their chronic medical conditions.

Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns is dedicated to advancing a pipeline of innovative therapeutic candidates. Its notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, an amine oxidase inhibitor. The company leverages its expertise in disease biology and medicinal chemistry, along with a capital-efficient drug discovery model and robust clinical development capabilities, to address significant unmet medical needs in both China and the global market.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, that specializes in developing small molecule therapies for severe, rare musculoskeletal diseases. Founded in 2017, the company employs a precision medicine approach to create innovative treatments targeting various muscle disorders, including Duchenne and Becker muscular dystrophies, as well as limb girdle muscular dystrophies. Utilizing its proprietary muscle-focused drug discovery platform, Edgewise integrates expertise in muscle biology and small molecule engineering to identify and develop therapies that address genetically defined muscle disorders. The company emphasizes a holistic drug discovery method that assesses integrated muscle function, enabling it to create orally bioavailable therapies aimed at improving outcomes for patients with significant unmet medical needs in neuromuscular and cardiac diseases.

Enliven Therapeutics is a clinical-stage precision oncology company based in Boulder, Colorado, focused on developing innovative small molecule therapies to enhance patient outcomes. Established in July 2019 by Sam Kintz, Joe Lyssikatos, and Anish Patel, the company employs a unique discovery process that leverages clinically validated biological targets alongside advanced chemistry. This methodology aims to overcome the limitations of current therapies by creating potentially first-in-class treatments that address critical challenges such as tolerability, combinability, resistance, and disease progression, particularly in cases involving brain metastases. Enliven's product pipeline includes ELVN-001, a selective small molecule kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia, and ELVN-002, an irreversible HER2 inhibitor designed to penetrate the central nervous system and act against various HER2 variants.

Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment specifically designed for cancer and cell biology research. The company offers advanced flow cytometers, including the Cytek Aurora and Cytek Northern Lights, as well as the DxP Athena system, which utilizes proprietary technology to enhance the detection of dim populations in a multicolor format. In addition, Cytek provides the QbSure quality control program to ensure the optimal performance of its cytometers and a range of cFluor reagents tailored for use in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence internationally with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company was previously known as Cytoville, Inc. before rebranding in August 2015.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Caris Life Sciences, Inc. is a biotechnology company specializing in molecular profiling and advanced diagnostic technologies aimed at improving cancer patient outcomes. Founded in 1987 and headquartered in Irving, Texas, with additional offices in Phoenix and Basel, the company develops solutions that leverage artificial intelligence and machine learning to analyze the molecular complexity of diseases. Caris offers a range of services, including anatomic pathology, drug development, and molecular analyses of patient samples, which include genomic, transcriptomic, and proteomic profiling. Their Comprehensive Oncology Data Explorer serves as a clinico-genomic data platform. By providing insights into DNA, RNA, and protein profiles, Caris enables healthcare professionals to make more precise and personalized treatment decisions for oncology and other complex diseases. The company operates through distributors across the United States, Europe, Australia, and globally, and has established strategic collaborations to enhance its offerings.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a primary cause of dry eye disease (DED). The company's portfolio includes a range of compounds designed to address the underlying causes of MGD and improve health outcomes for individuals suffering from ocular surface diseases, where effective treatment options are limited. Azura utilizes a novel drug delivery platform to enhance the efficacy of its therapies. The company is headquartered in Tel Aviv-Yafo, Israel, with operational presence in Australia and the United States, and is supported by a management team experienced in the development and commercialization of novel ocular treatments.

Nuvation Bio Inc. is a biopharmaceutical company dedicated to addressing unmet needs in oncology through the development of novel therapies for challenging cancers. Founded in 2018 and headquartered in New York, with an additional office in San Francisco, Nuvation Bio focuses on treating patients whose conditions have not responded to conventional treatments. The company's leading clinical-stage candidate, NUV-868, is a BD2-selective oral small molecule BET inhibitor that targets the BRD4 protein, which plays a crucial role in regulating tumor growth and differentiation. In addition to NUV-868, Nuvation Bio is advancing a proprietary small molecule Drug-Drug Conjugate platform aimed at enhancing therapeutic efficacy. The company’s comprehensive portfolio includes multiple drug development candidates designed to meet the specific needs of cancer patients.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

CoreMap, Inc. is dedicated to enhancing patient outcomes through advanced diagnostic technology tailored for electrophysiologists treating atrial fibrillation. Founded in 2016 and based in Winooski, Vermont, the company has developed a micro-electrode solution that allows for sequential mapping of tissue properties. This innovative technology addresses critical challenges in atrial fibrillation treatment, specifically poor spatial resolution and inadequate sample density. CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even in the presence of fibrillation, thereby enabling medical practitioners to offer more effective treatment options for patients.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.

I-Mab Biopharma (Shanghai) Co., Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, with additional offices in Beijing and Rockville, Maryland. Founded in 2016, the company focuses on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the fields of immuno-oncology and immuno-inflammation. I-Mab's diverse drug pipeline targets various therapeutic areas, including multiple myeloma, autoimmune diseases, pediatric growth hormone deficiency, and several cancer indications such as head and neck cancer. Key candidates in its portfolio include Uliledlimab, an antibody for solid tumors, along with Ragistomig and Givastomig, highlighting the company's commitment to developing transformative therapies for patients.

Erasca, Inc. is a clinical-stage precision oncology company based in San Diego, California, focused on discovering and developing therapies for cancers driven by the RAS/MAPK pathway. Founded in 2018, the company utilizes its artificial intelligence-driven oncology pattern recognition algorithm (OPRA) to analyze extensive datasets and uncover novel tumor biology, which aids in the identification of key oncogenes. Erasca's drug development pipeline includes Naporafenib, a pan-RAF inhibitor with potential applications in NRAS mutant melanoma and other RAS/MAPK pathway-driven tumors, as well as ERAS-007, an oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor. The company aims to provide precision oncology options through collaborations with academic and biopharmaceutical partners, ultimately seeking to offer innovative treatment solutions for patients.

NeuroPace, Inc. is a medical device company based in Mountain View, California, that specializes in developing and manufacturing implantable devices for treating neurological disorders, particularly epilepsy. The company's primary product is the Responsive Neurostimulator (RNS) System, designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers targeted electrical pulses to specific seizure onset areas. The RNS System comprises both implantable components, such as depth leads and cortical strip leads, and external products, including a programmer that facilitates communication with the implanted device. Founded in 1997, NeuroPace aims to transform the lives of individuals suffering from epilepsy by significantly reducing or eliminating seizures through its innovative technology. The company primarily generates revenue from sales of the RNS System to hospitals and medical facilities that perform the implantation procedures.

Kinnate Biopharma Inc. is a biopharmaceutical company based in San Diego, California, focused on developing small molecule kinase inhibitors for the treatment of genomically defined cancers. Founded in 2018, the company aims to create precision oncology therapeutics to address the needs of underserved patient populations. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is working on KIN003, which targets specific alterations in the FGFR2 and FGFR3 genes, and has other small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor. Kinnate Biopharma employs expertise in structure-based drug discovery and translational research to advance its pipeline of candidates aimed at treating cancers associated with specific oncogenic alterations.

Prelude Therapeutics is a clinical-stage precision oncology company based in Wilmington, Delaware, founded in 2016 by Krishna Vaddi. The company is focused on discovering and developing novel small-molecule therapies that target key mechanisms driving cancer cell growth, survival, and resistance, addressing significant unmet medical needs in oncology. Prelude's pipeline includes four clinical candidates: PRT1419, a selective inhibitor of MCL1; PRT2527, a selective CDK9 inhibitor; PRT3645, a next-generation CDK4/6 inhibitor; and PRT3789, a first-in-class SMARCA2/BRM protein degrader. Through these innovative therapies, Prelude aims to provide healthcare providers with potential treatment options to improve outcomes for patients battling cancer.

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company based in Seattle, Washington, that specializes in the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational endothelin receptor antagonist currently prepared for Phase III trials targeting IgA nephropathy and other primary glomerular diseases. In addition to atrasentan, Chinook is developing BION-1301, an investigational anti-APRIL monoclonal antibody evaluated in a Phase Ib trial for IgA nephropathy, and CHK-336, a preclinical candidate aimed at treating an undisclosed ultra-orphan kidney disease. Chinook Therapeutics is also engaged in research programs addressing other rare and severe chronic kidney conditions, including polycystic kidney disease.

Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Established in 2011, the company has developed therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of nasal congestion. Its primary products include the VivAer procedure for nasal airway obstruction and the RhinAer procedure for chronic rhinitis, both of which employ proprietary temperature-controlled technology. These solutions offer ENT physicians appealing alternatives to invasive surgery, allowing them to treat patients under local anesthesia with minimal to no downtime. Aerin Medical aims to meet the unmet needs of individuals suffering from chronic nasal airway conditions through its innovative and office-friendly product offerings.